1. Home
  2. OKE vs ARGX Comparison

OKE vs ARGX Comparison

Compare OKE & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ONEOK Inc.

OKE

ONEOK Inc.

HOLD

Current Price

$74.01

Market Cap

47.8B

Sector

Utilities

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$810.88

Market Cap

52.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OKE
ARGX
Founded
1906
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.8B
52.6B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
OKE
ARGX
Price
$74.01
$810.88
Analyst Decision
Buy
Strong Buy
Analyst Count
14
19
Target Price
$89.07
$979.22
AVG Volume (30 Days)
3.4M
345.7K
Earning Date
02-23-2026
02-26-2026
Dividend Yield
5.56%
N/A
EPS Growth
13.61
N/A
EPS
5.43
23.27
Revenue
$31,564,000,000.00
$3,683,281,000.00
Revenue This Year
$52.55
$91.44
Revenue Next Year
$8.52
$36.90
P/E Ratio
$13.65
$32.12
Revenue Growth
58.35
92.98
52 Week Low
$64.02
$510.06
52 Week High
$111.02
$934.62

Technical Indicators

Market Signals
Indicator
OKE
ARGX
Relative Strength Index (RSI) 53.54 43.44
Support Level $72.42 $797.48
Resistance Level $76.73 $818.78
Average True Range (ATR) 1.84 23.18
MACD 0.11 0.45
Stochastic Oscillator 57.01 46.84

Price Performance

Historical Comparison
OKE
ARGX

About OKE ONEOK Inc.

Oneok is a diversified midstream service provider specializing in natural gas gathering, processing, storage, and transportation and natural gas liquids transportation and fractionation. It also operates a refined product and crude oil segment connecting producers, refiners, and consumers. Operations are in the midcontinent, Permian, and Rocky Mountain regions.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: